Search research articles
Contact Us
Filters
Showing results (111-120 of 153) with videos related to
Page
of 16
Sort By:
Cancer Immunology Research
|
April 19, 2023
MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2
Ettai Markovits, Ortal Harush, Erez N Baruch, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 4, 2009
Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients
Michal J Besser, Ronnie Shapira-Frommer, Avraham J Treves, et al.
Molecular Carcinogenesis
|
April 7, 2020
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response
Michal J Besser, Orit Itzhaki, Guy Ben-Betzalel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma
Steven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.
Dermatology and Therapy
|
November 9, 2023
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
Åse Bratland, Eva Munoz-Couselo, Laurent Mortier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
Caroline Robert, Matteo S Carlino, Catriona McNeil, et al.
Lancet (London, England)
|
August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
The New England Journal of Medicine
|
September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer, Axel Hauschild, Mario Santinami, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2010
Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients
Michal J Besser, Ronnie Shapira-Frommer, Avraham J Treves, et al.
Page
of 16
Search research articles
Search
Showing results (111-120 of 153) with videos related to
Sort By:
Page
of 16
Cancer Immunology Research
|
April 19, 2023
MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2
Ettai Markovits, Ortal Harush, Erez N Baruch, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 4, 2009
Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients
Michal J Besser, Ronnie Shapira-Frommer, Avraham J Treves, et al.
Molecular Carcinogenesis
|
April 7, 2020
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response
Michal J Besser, Orit Itzhaki, Guy Ben-Betzalel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma
Steven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.
Dermatology and Therapy
|
November 9, 2023
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
Åse Bratland, Eva Munoz-Couselo, Laurent Mortier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
Caroline Robert, Matteo S Carlino, Catriona McNeil, et al.
Lancet (London, England)
|
August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
The New England Journal of Medicine
|
September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer, Axel Hauschild, Mario Santinami, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2010
Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients
Michal J Besser, Ronnie Shapira-Frommer, Avraham J Treves, et al.
Page
of 16